William John Sibold Sells 1,577 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CEO William John Sibold sold 1,577 shares of the business’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $492.42, for a total transaction of $776,546.34. Following the transaction, the chief executive officer owned 148,497 shares in the company, valued at approximately $73,122,892.74. This trade represents a 1.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

William John Sibold also recently made the following trade(s):

• On Thursday, December 4th, William John Sibold sold 2,400 shares of Madrigal Pharmaceuticals stock. The shares were sold at an average price of $575.34, for a total value of $1,380,816.00.

Madrigal Pharmaceuticals Stock Performance

NASDAQ MDGL opened at $500.39 on Wednesday. The stock has a market capitalization of $11.36 billion, a price-to-earnings ratio of -38.46, a PEG ratio of 4.84 and a beta of -1.00. The business’s 50 day moving average is $556.89 and its two-hundred day moving average is $462.94. Madrigal Pharmaceuticals, Inc. has a 12-month low of $265.00 and a 12-month high of $615.00. The company has a current ratio of 3.44, a quick ratio of 3.26 and a debt-to-equity ratio of 0.54.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($5.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.01) by ($3.07). Madrigal Pharmaceuticals had a negative net margin of 39.04% and a negative return on equity of 41.50%. Research analysts expect that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current year.

Analyst Ratings Changes

MDGL has been the topic of a number of research analyst reports. Bank of America raised shares of Madrigal Pharmaceuticals from an “underperform” rating to a “neutral” rating and boosted their price objective for the stock from $266.00 to $445.00 in a report on Monday, November 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research note on Thursday, January 22nd. TD Cowen reaffirmed a “buy” rating on shares of Madrigal Pharmaceuticals in a research note on Monday, January 12th. Citizens Jmp lifted their price objective on Madrigal Pharmaceuticals from $527.00 to $745.00 and gave the stock a “market outperform” rating in a report on Tuesday, January 20th. Finally, JMP Securities set a $527.00 target price on Madrigal Pharmaceuticals in a report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $654.73.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Teacher Retirement System of Texas grew its stake in shares of Madrigal Pharmaceuticals by 9.6% during the 2nd quarter. Teacher Retirement System of Texas now owns 3,860 shares of the biopharmaceutical company’s stock valued at $1,168,000 after buying an additional 338 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in Madrigal Pharmaceuticals by 388.3% in the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 15,288 shares of the biopharmaceutical company’s stock valued at $7,012,000 after acquiring an additional 12,157 shares during the last quarter. Voya Investment Management LLC boosted its holdings in Madrigal Pharmaceuticals by 16.3% in the third quarter. Voya Investment Management LLC now owns 59,437 shares of the biopharmaceutical company’s stock valued at $27,261,000 after acquiring an additional 8,347 shares during the last quarter. Calamos Advisors LLC purchased a new stake in Madrigal Pharmaceuticals during the third quarter valued at about $2,057,000. Finally, Marex Group plc purchased a new stake in Madrigal Pharmaceuticals during the second quarter valued at about $548,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.